Location: Cincinnati, OH
PDS Biotechnology is developing drugs targeting the $50 billion cancer market and $18 billion infection disease market. PDS has a very strong IP position and animal-tested technology of drug therapies for these markets. The technology's efficacy has also been demonstrated in the human model system. The National Cancer Institute has reviewed the technology and has awarded an SBIR contract to develop a cancer therapy. The management team is made up of proven biotechnology industry veterans. PDS is currently a Cincinnati-based co. seeking to relocate to the mid-Atlantic region to be closer to the major Pharmaceutical Co.'s. PDS is seeking to raise $2.5M - $3.0M from biotechnology-focused VC's and angels.